BRCA2 and cancer: To investigate whether disrupting RAD51-BRCA2-mediated HR together with PARP inhibition could be a feasible strategy to target cancer aggressiveness, we assessed the effects of RS-35d, S-35d and R-35d on cancer cell proliferation, migration and survival.